A 83-01
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively[1].
Product Specifications
CAS Number
[909910-43-6]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Organoid; TGF-β Receptor
Type
Reference compound
Related Pathways
Stem Cell/Wnt; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/A-83-01.html
Purity
99.33
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5
Molecular Formula
C25H19N5S
Molecular Weight
421.52
Precautions
H302, H315, H319, H335
References & Citations
[1]Tojo M, et al. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci. 2005 Nov;96 (11) :791-800.|[2]Yamamura S, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012 Jan 1;130 (1) :20-8.|[3]Taniguchi Y, et al. Enhanced antitumor efficacy of folate-linked liposomal Adriamycin with TGF-β type I receptor inhibitor. Cancer Sci. 2010 Oct;101 (10) :2207-13.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ALK4; ALK5; ALK7
Citation 01
Acta Pharm Sin B. 2025 Sep 19.|Acta Pharmacol Sin. 2024 Dec;45 (12) :2611-2624.|Acta Pharmacol Sin. 2025 May;46 (5) :1404-1418.|Adv Sci (Weinh) . 2022 Sep;9 (26) :e2202505.|Adv Sci (Weinh) . 2024 Dec 4:e2408852.|Adv Sci (Weinh) . 2024 Nov 25:e2401227.|Adv Sci (Weinh) . 2024 Nov;11 (43) :e2402299.|Adv Sci (Weinh) . 2025 Nov 3:e09151.|Am J Physiol Cell Physiol. 2023 Jul 1;325 (1) :C344-C361.|Biofabrication. 2025 Aug 12;17 (4) .|Biol Reprod. 2025 May 13:ioaf108.|Biomed Pharmacother. 2025 May 1:187:118094.|bioRxiv. 2024 August 11.|bioRxiv. 2024 Feb 27.|bioRxiv. 2024 July 22.|bioRxiv. 2024 November 18.|bioRxiv. 2025 April 14.|bioRxiv. 2025 April 30.|bioRxiv. 2025 Aug 30.|bioRxiv. 2025 Aug 8:2025.08.08.669417.|bioRxiv. 2025 January 28.|bioRxiv. 2025 May 12.|Br J Cancer. 2025 Aug 26.|Br J Cancer. 2025 Jan;132 (1) :126-136.|Cancer Biomark. 2025 Oct;42 (10) :18758592251390145.|Cancer Commun (Lond) . 2025 Nov 10.|Cancer Res. 2025 May 2;85 (9) :1628-1643.|Cancer Res. 2025 Nov 6.|Cancer Res. 2025 Oct 9.|Cell Death Dis. 2024 Aug 3;15 (8) :559.|Cell Death Dis. 2025 Aug 30;16 (1) :660.|Cell Prolif. 2023 Jan;56 (1) :e13320.|Cell Prolif. 2024 Jun;57 (6) :e13599.|Cell Rep Med. 2025 Feb 18;6 (2) :101966.|Cell Rep. 2022 Jul 12;40 (2) :111053.|Cell Rep. 2023 May 23;42 (6) :112546.|Cell Stem Cell. 2022 Sep 1;29 (9) :1346-1365.e10.|Cell Stem Cell. 2025 Mar 6;32 (3) :391-408.e11.|Cell Stem Cell. 2025 Mar 6;32 (3) :409-425.e8.|Cell. 2024 Nov 14;187 (23) :6566-6583.e22.|Cells. 2024 Aug 31.|Commun Biol. 2025 Jul 4;8 (1) :995.|Engineering. 2025 Aug 27.|FASEB J. 2020 Aug;34 (8) :11185-11199.|FASEB J. 2023 Dec;37 (12) :e23279.|FASEB J. 2023 Jul;37 (7) :e22983.|Front Med. 2021 Sep 23;8:746298.|Genome Med. 2024 Apr 24;16 (1) :60|Gynecol Oncol. 2019 Jun;153 (3) :639-650.|Hum Cell. 2024 Nov 4;38 (1) :13.|In Vitro Model. 2025 Mar 5;4 (1) :31-44.|Int J Cancer. 2024 May 15;154 (10) :1814-1827.|Int J Mol Sci. 2023 Dec 29;25 (1) :477.|Int J Mol Sci. 2025 May 31;26 (11) :5306.|Int J Radiat Oncol Biol Phys. 2024 Mar 1;118 (3) :817-828.|iScience. 2025 Apr 3;28 (5) :112344.|iScience. 2025 Jan 17;28 (2) :111827.|iScience. 2025 Oct 17.|J Pharm Anal. 2024 Mar;14 (3) :335-347.|J Transl Med. 2021 Dec 7;19 (1) :497.|J Vis Exp. 2025 Jan 31: (215) .|Methods Mol Biol. 2022:2454:811-827.|Methods Mol Biol. 2024:2767:1-18.|Methods Mol Biol. 2024:2767:43-52.|Methods Mol Biol. 2024:2767:53-62.|Methods Mol Biol. 2025 May 17.|Methods Mol Biol. 2025 May 22.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Mol Oncol. 2024 Mar;18 (3) :547-561.|Nano Res. 03 August 2022.|Nat Cell Biol. 2022 Jun;24 (6) :858-871.|Nat Commun. 2022 Sep 6;13 (1) :5237.|Nat Commun. 2025 Aug 26;16 (1) :7954.|Nat Genet. 2024 Feb;56 (2) :294-305.|Nat Methods. 2025 Mar;22 (3) :510-519.|Nat Photonics. 2025 Jul 10.|Nat Protoc. 2023 May;18 (5) :1584-1620.|Patent. US20220389379A1.|Patent. US20240319170A1|Patent. US20240344020A1|Patent. US20240344020A1.|Patent. US20250129329A1.|Redox Biol. 2025 Jun:83:103615.|Reprod Toxicol. 2024 Jan:123:108522.|Res Sq. 2025 Jul 14.|Research Square Preprint. 2021 Jan.|Sci Adv. 2021 Apr 14;7 (16) :eabb2213.|Sci Adv. 2023 Dec 22;9 (51) :eadi5683.|Sci Adv. 2025 May 9;11 (19) :eadr3173.|Sci Adv. 2025 Sep 5;11 (36) :eadz0808.|Sci Rep. 2025 Mar 12;15 (1) :8531.|SSRN. 2024 May 23.|SSRN. 2024 May 30.|SSRN. 2025 Jun 3.|SSRN. 2025 May 27.|Stem Cell Res Ther. 2024 Dec 18;15 (1) :478.|Stem Cell Res Ther. 2025 Mar 11;16 (1) :132.|Stem Cell Res Ther. 2025 Oct 8;16 (1) :547.|Stem Cells Int. 2025 Jul 11:2025:5105796.|Theranostics. 2021 Mar 14;11 (11) :5539-5552.|Theranostics. 2024 Jan 1;14 (3) :1049-1064.|University of California. 2025.|Cell Signal. 2025 Jun 17:111946.|Genes Dis. 2025 May 2.|J Biol Chem. 2022 Sep;298 (9) :102374.|Nat Commun. 2025 Jul 17;16 (1) :6575.|Science. 2020 Dec 4;370 (6521) :eaay2002.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15188729 1 Vial
Lentiviral mouse Cdc42se2 shRNA (UAS) - Lentiviral mouse Cdc42se2 shRNA (UAS) (25)
Ask
View Details